Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis–Related Diabetes

Open access
Moran, Antoinette, Becker, Dorothy, Casella, Samuel J., Gottlieb, Peter A., Kirkman, M. Sue, Marshall, Bruce C., Slovis, Bonnie, the CFRD Consensus Conference Committee·2010·Diabetes Care

Abstract

Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in subjects with cystic fibrosis (CF).A consensus conference on CFRD was cosponsored by the Cystic Fibrosis Foundation (CFF), the American Diabetes Association (ADA), and the Pediatric Endocrine Society (PES) in September 2009.The committee's evidencebased recommendations for clinical management of CFRD are published in this issue of Diabetes Care.This review article describes the epidemiology, pathogenesis, and prognostic implications of CFRD. EpidemiologyCFRD is part of a continuum of glucose tolerance abnormalities, ranging from normal glucose tolerance (NGT), to impaired glucose tolerance (IGT), to CFRD without fasting hyperglycemia (CFRD FHϪ), to CFRD with fasting hyperglycemia (CFRD FHϩ) (Fig. 1).Unlike patients with type 1 diabetes, those with CFRD do not develop complete absence of insulin secretion.At the other end of the spectrum, few CF patients have truly normal glucose metabolism.Approximately 20% of children who are categorized as having NGT based on their fasting and 2-h oral glucose tolerance test (OGTT) glucose levels have glucose elevation Ͼ200 mg/dl (11.1 mmol/l) mid-OGTT, which is termed indeterminate glycemia (INDET) (1).As in the general population where INDET is a risk factor for progression to diabetes (2), INDET in children with CF is associated with early development of CFRD (1).Home continuous glucose monitoring (CGM) has shown that intermittent, asymptomatic hyperglycemia is common even in CF patients whose OGTT is normal, but the prognostic significance of these early impairments in glucose metabolism is unknown (3,4).Impaired fasting glucose has also been described in CF (5,6).CFRD is present in about 20% of adolescents and 40 -50% of adults with CF (7) (Fig. 2).It is rare in childhood but has been described in children of all ages including infants (8 -11).Beginning in the teenage years, the incidence is ϳ3%, with some but not all centers reporting an overall female predominance (7,12).In younger individuals CFRD FHϪ predominates, but the prevalence of fasting hyperglycemia rises with age (7).Diabetes is associated with more severe CF gene mutations, increasing age, worse pulmonary function, undernutrition, liver dysfunction, pancreatic insufficiency, and corticosteroid use (12-15).Pathophysiology CFRD shares features of both type 1 and type 2 diabetes, but has enough pathophysiological and clinical differences to warrant separate diagnostic classification (Table 1).As in type 1 diabetes, individuals with CFRD are not obese, it often occurs in young people, insulin insufficiency is the primary defect, and metabolic syndrome features (hyperlipidemia, hypertension, visceral adiposity) are not usually present.Clinical management is similar to type 1 diabetes in the honeymoon phase.As in type 2 diabetes, this is not an autoimmune disease, insulin resistance is present (albeit usually mild), and ketosis is rare.Genetically, CFRD may be related to type 2 diabetes, as described below.Insulin insufficiency.Reduced ␤-cell mass leading to insulin insufficiency is the hallmark of CFRD.The CF gene defect leads to abnormal or absent CF transmembrane conductance regulator (CFTR), a chloride channel that also influences sodium and water transport.Thick, viscous secretions cause inflammation, obstruction, and destruction of small ducts in the lungs, pancreas, liver, and reproductive organs.Autopsy findings include fibrosis and atrophy of the pancreas with ϳ50% reduction of the total islet mass (16 -18).Multiple studies have shown impaired first-phase insulin secretion in response to glucose, arginine, or glucagon, even in subjects with .In response to oral glucose, the earliest defect is delayed insulin secretion, followed over time by a progressively diminished total insulin response (22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32).The ␤-cell destruction is not complete and residual endogenous insulin secretion is present, so these patients are not prone to ketosis.The lack of ketosis may also be related to low glucagon levels.While fasting glucagon levels are normal, CF patients are not able to appropriately increase glucagon secretion in response to arginine or hypoglycemia (21,24), consistent with reduced ␣-cell mass.Incretin levels (gastric

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc10-1279

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 258

Metadata

Authors
Moran, A., Becker, D., Casella, S. J., Gottlieb, P. A., Kirkman, M. S., Marshall, B. C., Slovis, B., & the CFRD Consensus Conference Committee
Venue
Diabetes Care
Published
2010-12-01
Volume
33
Issue
12
Pages
2677-2683
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2167789521
Cited by
258
References
70
FWCI
10.58
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis–Related Diabetes. https://app.cochat.ai/papers/10.2337/dc10-1279
The paper
Moran, A., Becker, D., Casella, S. J., Gottlieb, P. A., Kirkman, M. S., Marshall, B. C., Slovis, B., & the CFRD Consensus Conference Committee. (2010). Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis–Related Diabetes. Diabetes Care. https://doi.org/10.2337/dc10-1279

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.